PRJNA575377
CDK4/6 inhibition reverses MEIS2 inhibition of IMiD therapy in myeloma
We have discovered that MEIS2 is aberrantly expressed in myeloma cells to predispose patients to adverse overall survival in IMiD therapy by suppressing the anti-myeloma interferon response and inhibiting the CRL4-CRBN E3 ubiquitin ligase in proximal IMiD signaling. Inhibition of CDK4/6 reverses both, uncovering a novel dual mechanism by which CDK4/6 inhibition augments IMiD's anti-myeloma activity and suggesting a potential clinical benefit to targeting CDK4/6 in combination with IMiD.